Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Download Publication
28 Jan 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

8 Dec 2021

Aptar Pharma discusses an antibody nasal spray for SARS-CoV-2

Publications, Pharmaceutical, Product Solutions, Innovation & Insights

Read More
18 Nov 2021

Delivering On The Promises of Intranasal Vaccination

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
2 Nov 2021

Successfully Balancing The Needs of The Planet With The Needs of The Patient

Publications, Pharmaceutical, Product Solutions, Sustainability, Innovation & Insights, Device Innovations

Read More
26 Oct 2021

Using digital healthcare to improve patient compliance and adherence

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
1 15 16 17 18 19 27
Back To Top